Treatment of oxidative stress with chelation therapy.

Published on Dec 1, 2012in Archives of Ophthalmology
· DOI :10.1001/JAMAOPHTHALMOL.2013.1306
Marco A. Zarbin58
Estimated H-index: 58
Sources
Abstract
mentosa. Hahn et al 1 have documented higher iron levels in eyes of patients with age-related macular degeneration than in eyes of age-matched controls (particularly chelatable iron deposition in the retinal pigment epithelium and Bruch membrane). Because iron catalyzes the Fenton reaction (which produces hydroxyl radical), these results may mean that ironmediated oxidative stress contributes to retinal degeneration in age-related macular degeneration. Furthermore, mice deficient in the ferroxidases ceruloplasmin and hephaestin accumulate iron in the retina and subsequently have retinal degeneration with features of age-related macular degeneration. 2,3 In these mice, iron chelation with the orally absorbed and cellpermeant iron chelator deferiprone (Ferriprox) ameliorated oxidative stress and protected against iron overload–induced retinal degeneration. 4 Because other investigators showed that the iron chelator deferoxamine can protect against retinal light damage and retinal ischemia reperfusion injury, Hadziahmetovicetal 5 decidedtotesttherecentlyUSFoodandDrug Administration–approved drug deferiprone because it is orally absorbed and has not been associated with retinal toxic effects in patients or mice. In the current issue of Translational Vision Science & Technology, Hadziahmetovic and colleagues report the ability of deferiprone to preventretinaldegenerationin2distinctpreclinicalmodels: sodium iodate (NaIO3)–induced retinal degeneration and the rd6 mouse. Sodium iodate is a retinotoxin, anditssystemicadministrationrelativelyselectivelydamagesretinalpigmentepitheliumandphotoreceptors.The rd6mutationaffectstheMfrpgene,afrizzled-relatedgene expressed in the retinal pigment epithelium. Mice homozygous for this mutation have an early-onset, slowly progressive loss of photoreceptors. Theinvestigatorsfoundthatsystemicpretreatmentand concomitant treatment with deferiprone modestly improved photoreceptor survival and markedly improved retinal pigment epithelium survival in the NaIO3model. Deferiprone also modestly improved photoreceptor survivalinrd6mice.Whatisthemechanismbywhichdeferiprone exerts these effects? The investigators found that deferiprone diminished NaIO3-induced upregulation of antioxidantandcomplementgenes(C3)causedbyNaIO3. Deferiprone also protected against NaIO3-induced reduction in the levels of visual cycle genesRhoandRpe65, consistent with retinal protection. These and other findings indicate that deferiprone reduces oxidative stress. The finding that deferiprone treatment ameliorated hereditary retinal degeneration due to the rd6 mutation in B6.C3Ga-Mfrprd6/J mutant mice is consistent with the previous work of Obolensky et al, 6 who found that deferoxamine provides functional and structural retina rescueintherd10mousemodelofretinitispigmentosa.Presumably, amelioration of oxidative stress also reduces photoreceptor damage in these models of human retinitis pigmentosa. 7 The dose of deferiprone used in this study is about 3-fold higher than that given to humans treated for systemic iron overload. In future studies, the investigators will examine both dose response and dosing frequency. The apparent lack of retinal toxic effects of deferiprone combined with the evidence that it can protect the retina against iron overload, NaIO3, the rd6 mutation, and light damage suggest that it merits further investigation for potential treatment of diverse retinal disorders. The results of these deferiprone experiments indicate that iron chelation may serve as a protective agent not only against iron overload–induced retinal degeneration but also against retinal disorders in which iron dysregulation is not the primary cause. In a Research Highlight in Translational Vision Science & Technology, Fliesler 8 notes that “drug repurposing” is a current buzz phrase in translational medicine. Deferiprone has been used for the treatment of thalassemia major and is currently being used in clinical trials in the United States for treatment of contrast-induced acute kidney disease and for slowing the progression of chronic kidney disease. The present article by Hadziahmetovic et al 5 may lead to such repurposing of deferiprone and thus represents yet another potential application of chelator-based therapeutics.
📖 Papers frequently viewed together
2 Citations
20112.74PLOS ONE
8 Authors (James Randazzo, ..., Peter F. Kador)
14 Citations
41 Citations
References8
Newest
In a report by Hadziahmetovic et al,1 oral administration of an iron chelator deferiprone (Ferriprox), which was recently approved by the Food and Drug Administration, showed substantial protection against retinal degeneration both in a chemically induced (NaIO3) mouse model as well as in a rd6 mouse, which exhibits a hereditary, slowly progressing retinal degeneration that mainly affects the RPE and photoreceptor cells. These authors previously demonstrated that this iron chelator can spare the...
2 CitationsSource
#1Majda Hadziahmetovic (UPenn: University of Pennsylvania)H-Index: 14
#2Miroslav Pajic (UPenn: University of Pennsylvania)H-Index: 26
Last. Joshua L. Dunaief (UPenn: University of Pennsylvania)H-Index: 44
view all 13 authors...
Purpose To investigate the effect of the iron chelator deferiprone (DFP) on sodium iodate (NaIO3)–induced retinal degeneration and on the hereditary retinal degeneration caused by the rd6 mutation.
26 CitationsSource
#1Alexey Obolensky (HUJI: Hebrew University of Jerusalem)H-Index: 19
#2Eduard Berenshtein (HUJI: Hebrew University of Jerusalem)H-Index: 20
Last. Eyal Banin (HUJI: Hebrew University of Jerusalem)H-Index: 49
view all 10 authors...
Abstract Iron-associated oxidative injury plays a role in retinal degeneration such as age-related macular degeneration and retinitis pigmentosa. The metallo-complex zinc–desferrioxamine (Zn/DFO) may ameliorate such injury by chelation of labile iron in combination with release of zinc. We explored whether Zn/DFO can affect the course of retinal degeneration in the rd10 mouse model of retinitis pigmentosa. Zn/DFO-treated animals showed significantly higher electroretinographic responses at 3 and...
46 CitationsSource
#1Majda Hadziahmetovic (UPenn: University of Pennsylvania)H-Index: 14
#2Ying Song (UPenn: University of Pennsylvania)H-Index: 21
Last. Joshua L. Dunaief (UPenn: University of Pennsylvania)H-Index: 44
view all 12 authors...
Iron-induced oxidative stress may exacerbate age-related macular degeneration (AMD). Ceruloplasmin/Hephaestin double-knockout (DKO) mice with age-dependent retinal iron accumulation and some features of AMD were used to test retinal protection by the oral iron chelator deferiprone (DFP).Cultured retinal pigment epithelial (ARPE-19) cells and mice were treated with DFP. Transferrin receptor mRNA (Tfrc), an indicator of iron levels, was quantified by qPCR. In mice, retinal oxidative stress was ass...
76 CitationsSource
#1Majda Hadziahmetovic (UPenn: University of Pennsylvania)H-Index: 14
#2Tzvete Dentchev (UPenn: University of Pennsylvania)H-Index: 28
Last. Joshua L. Dunaief (Scheie Eye Institute)H-Index: 44
view all 12 authors...
Iron is a trace element that functions as a component of many proteins and enzymes, including oxygen-carrying proteins hemoglobin and myoglobin, cytochromes, and other enzymes that are involved in oxidation or reduction. Although iron is an essential metabolic component, it is also a potent generator of damaging free radicals that can cause oxidative stress. Regulation of ferrous iron levels is critical for meeting physiologic demand while preventing the toxicity associated with iron overload.1 ...
107 CitationsSource
#1Keiichi Komeima (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 13
#2Brian S. Rogers (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 9
Last. Peter A. Campochiaro (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 121
view all 3 authors...
Retinitis pigmentosa (RP) is a heterogeneous group of diseases in which one of a wide variety of mutations selectively causes rod photoreceptor cell death. After rods die, cone photoreceptors gradually die resulting in blindness. Antioxidants reduce cone cell death in rd1/rd1 mice indicating that cones die from oxidative damage in that model of rapidly progressive RP. In this study, we sought to determine if this observation could be generalized to models of other types of RP, rd10/rd10 mice, a ...
204 CitationsSource
#1Paul Hahn (UPenn: University of Pennsylvania)H-Index: 28
#2Y. Qian (UPenn: University of Pennsylvania)H-Index: 3
Last. Joshua L. Dunaief (UPenn: University of Pennsylvania)H-Index: 44
view all 7 authors...
Abstract Mechanisms of brain and retinal iron homeostasis have become subjects of increased interest after the discovery of elevated iron levels in brains of patients with Alzheimer's disease and retinas of patients with age-related macular degeneration. To determine whether the ferroxidase ceruloplasmin (Cp) and its homolog hephaestin (Heph) are important for retinal iron homeostasis, we studied retinas from mice deficient in Cp and/or Heph. In normal mice, Cp and Heph localize to Muller glia a...
222 CitationsSource
#1Paul Hahn (UPenn: University of Pennsylvania)H-Index: 28
#2Ann H. MilamH-Index: 63
Last. Joshua L. DunaiefH-Index: 44
view all 3 authors...
Objective To investigate whether iron is involved in the pathogenesis of age-related macular degeneration (AMD). Methods Postmortem AMD-affected (nonexudative or exudative) and healthy maculas were studied using the 3, 3′-diaminobenzidine–enhanced Perls Prussian blue stain. The Perls Prussian blue stain was quantified by computer-assisted analysis of digital images. To determine whether the iron was chelatable, sections treated with the iron chelator deferoxamine were compared with adjacent, non...
208 CitationsSource
Cited By1
Newest
#1Michail S. Kukharsky (RSMU: Russian National Research Medical University)H-Index: 11
#2Veronika I. Skvortsova (RSMU: Russian National Research Medical University)H-Index: 15
Last. Vladimir L. Buchman (Cardiff University)H-Index: 46
view all 4 authors...
Recent progress in understanding the pathological changes in the nervous system and in certain other body systems (e.g., immune system) that lead to the development and progression of amyotrophic lateral sclerosis (ALS) revealed a number of molecular and cellular processes that can potentially be used as therapeutic targets. Many of these processes are compromised not only in ALS but also in other diseases and a repertoire of drugs able to restore, at least partially, their functionality has bee...
4 CitationsSource